Correspondingly, deletion of Peli1 enhances Aβ phagocytosis and clearance in Alzheimer’s disease, implicating Peli1 as a therapeutic target with significant potential for the treatment of microglia-mediated neurological disease. This evidence concerns the gene PELI1 and early-onset autosomal dominant Alzheimer disease.